The short version of Heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-10. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
The geography cone snail is highly venomous; live specimens should be handled with extreme caution. C. geographus has the most toxic sting known among Conus species and there are reports for about 36 human fatalities over the past 300 years. The venom has a median lethal dose in the range of 0.012–0.030 mg/kg. The venom of the geography cone snail is a complex mix of hundreds of different toxins that is delivered through a toxoglossan radula, a harpoon-like tooth propelled from an extendable proboscis. There is no antivenom for a cone snail sting, and treatment consists of keeping victims alive until symptoms wear off. The geography cone is also known colloquially as the "cigarette snail", a gallows humor exaggeration implying that, when stung by this creature, the victim will have only enough time to smoke a cigarette before dying. In reality, even the most venomous cone snails take about one to five hours to kill a healthy human, though medical care must still be prompt as, without it, death is almost certain. Among the compounds found in cone snail venom are proteins which, when isolated, have great potential as pain-killing drugs. Research shows that certain component proteins of the venom target specific human pain receptors and can be up to 10,000 times more effective than morphine, without morphine's addictive properties and side effects. Conotoxin-G is a toxin derived from the venom of C. geographus. Only 15–20 of the venom's 100–200 toxic peptides are used for feeding.
=== Uniform === Until 1914 the distinguishing colour of the Don Cossack Host was red, worn on the cap bands and wide trouser stripes of a dark blue uniform of the loose-fitting cut common to the Steppe Cossacks. Tall lambskin hats were worn on occasion, with red cloth tops edged in white lace. Silver metal scrolls were worn on the headdress to denote the distinguished conduct of individual regiments. Officers had silver braiding on their collars and epaulettes, plus silver/black girdles. Shoulder-straps of other ranks were the same dark blue as the caftan (coat). A whip was used instead of spurs. Prior to 1908, individual cossacks from all Hosts were required to provide their own uniforms, together with horses and harness. The size and relative affluence of the Don Cossack Host permitted the setting up of communally owned clothing factories. In 1908, a khaki field tunic was adopted, replacing the dark blue coats or white summer blouses previously worn for ordinary duties. The blue riding breeches with broad red stripes long characteristic of the Don Host, continued to be worn even on active service during both World Wars. The Don Cossack Battery of the Imperial Guard wore a "Tsar's green" uniform, a dark shade common to the army, with the black and red distinctions of the artillery as a branch.
Active mobility of these endodermal epithelial cells forms two layers in both the re-aggregate and the re-generating tip of the excised tissue. As these two layers are established, a patterning process takes place to form heads and feet.
Sources: en.wikipedia.org
=== Molecular structure of Cu(II)-histidine and ATCUN Motif === Sarkar solved the structure of the copper(II)-histidine molecule used for the treatment of Menkes disease. He discovered the ATCUN (Amino terminal Cu(II), Ni(II) binding) motif of proteins and peptides.
Olaf College Elio Di Rupo (born 1951), Prime Minister of Belgium Israel Shahak (1933–2001), Israeli chemist and civil-rights activist Margaret Thatcher (1925–2013), Prime Minister of the United Kingdom (1979–1990), research chemist at BX Plastics
In 2018, Schleip spearheaded the Fascial Net Plastination Project (FNPP), ananatomical research initiative designed to plastinate and study the human fascial network. The FNPP brought together experts in anatomy, dissection, and plastination, to plastinate a complete human fascia specimen. The project created a full-body human fascia plastinate named FR:EIA (Fascia Revealed: Educating Interconnected Anatomy). FR:EIA was unveiled at the 2021 Fascia Research Congress and is currently on display at the Body Worlds exhibition in Berlin.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.